ArticleLeukemia & lymphoma2020
Clinical outcomes and characteristics of patients with
Article in Leukemia & lymphoma, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Article
- Limited Survival Benefit and High Healthcare Utilization With AML-Directed Therapy in Older Patients With TP53 -Mutated Acute Myeloid Leukemia.American journal of hematology · 2026Article
- TP53 Amplification, a Rare but Recurrent Alteration in Myeloid Neoplasms.Genes, chromosomes & cancer · 2026Article
- A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.Blood advances · 2026Article
- Structural and Functional Analysis of GGPPS Inhibition as a Therapeutic Mechanism for Acute Myeloid Leukemia (AML).Research square · 2025Article
- Article
- Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients.International journal of hematology · 2025Article
- Review
- Overall survival in TP53-mutated AML and MDS.Annals of hematology · 2024Article
- The roles of ubiquitination in AML.Annals of hematology · 2024Review
- Therapy-Related Myeloid Neoplasm: Biology and Mechanistic Aspects of Malignant Progression.Biomedicines · 2024Review
- Unmet Horizons: Assessing the Challenges in the Treatment ofJournal of clinical medicine · 2024Review
- Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML.Blood advances · 2024Review
- Pharmacological reactivation of p53 in the era of precision anticancer medicine.Nature reviews. Clinical oncology · 2024Review
- Article
- Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS.Blood advances · 2023Article
- Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia.Leukemia · 2023Article
- Article
- TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.Cancer discovery · 2022Review
- Are We Moving the Needle for Patients withCancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Mutations in the tumor suppressor gene
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.